FirmaIQ
Org.nr 815 643 062 2023 → 2024 Year-over-year analysis

ADESSO BIOPRODUCTS AS: årsregnskap 2024 vs 2023

Shrank 39% on revenue, weaker earnings

approved 2025-03-18; registry 2025-05-15; journal 2025 402559

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2024 with 2023 for ADESSO BIOPRODUCTS AS. Revenue 85.69m NOK → 52.54m NOK (-38.7%). Net result +3.76m NOK → +2.12m NOK. Equity 41.61m NOK → 43.73m NOK.

On the constructive side: equity strengthened; cash rose. Pressures included: revenue fell; operating result weakened; net result weakened.

Also worth watching: cogs fell. All figures are taken from the published annual accounts for ADESSO BIOPRODUCTS AS.

At a glance

Scorecard

Revenue
85.69m NOK 52.54m NOK
-38.7%
Operating result
+5.81m NOK +2.66m NOK
-54.1%
Net result
+3.76m NOK +2.12m NOK
-43.5%
Equity
41.61m NOK 43.73m NOK
+5.1%
Cash
18.21m NOK 21.89m NOK
+20.3%
Total assets
66.31m NOK 59.85m NOK
-9.7%

What improved

  • ↑

    Equity strengthened

    Book equity 41.61m NOK → 43.73m NOK (equity ratio 62.7% → 73.1%). Calculated

  • ↑

    Cash rose

    Bank deposits 18.21m NOK → 21.89m NOK (+20.3% YoY). Calculated

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 85.69m NOK to 52.54m NOK (-38.7% YoY). Calculated

  • ↓

    Operating result weakened

    Operating result +5.81m NOK → +2.66m NOK (op. margin 6.8% → 5.1%). Calculated

  • ↓

    Net result weakened

    Net result +3.76m NOK → +2.12m NOK (net margin 4.4% → 4.0%). Calculated

  • ↓

    Payroll up without matching revenue

    Salary cost 16.66m NOK → 17.91m NOK (19% → 34% of revenue). Calculated

Things to notice

  • ·

    COGS fell

    COGS / varekostnad 41.17m NOK → 12.64m NOK (-69.3% YoY). Calculated